Paul G. Allen Frontiers Group    [to 28 Mar 2020]
Press Release
No new digest content identified.
BMGF – Gates Foundation  [to 28 Mar 2020]
No new digest content identified.
Bill & Melinda Gates Medical Research Institute    [to 28 Mar 2020]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.
CARB-X   [to 28 Mar 2020]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.
CEPI – Coalition for Epidemic Preparedness Innovations  [to 28 Mar 2020]
Latest News
Norway intensifies COVID-19 fight with NOK2.2 billion donation to CEPI
01 Apr 2020
Clinton Health Access Initiative, Inc. (CHAI)  [to 28 Mar 2020]
News & Press Releases
No new digest content identified.
 EDCTP    [to 28 Mar 2020]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
3 April 2020
Emergency funding of COVID-19 research among EDCTP 2020 calls for proposals
Today, EDCTP is publishing seven 2020 calls for proposals to support clinical research on poverty-related diseases, including neglected infectious diseases, and research capacity development in sub-Saharan Africa. The calls represent an investment of more than €80 million.

1 April 2020
Professor Gita Ramjee passed away on 31 March 2020
Yesterday, Professor Gita Ramjee, Chief Scientific Officer of the Aurum Institute in South Africa, passed away due to complications of a COVID-19 infection. Many in the EDCTP General Assembly, the Scientific Advisory Committee and the Secretariat worked with her and…
Emory Vaccine Center    [to 28 Mar 2020]
No new digest content identified.
European Medicines Agency  [to 28 Mar 2020]
News & Press Releases ·
Press release: EMA provides recommendations on compassionate use of remdesivir for COVID-19
CHMP, Last updated: 03/04/2020

News: International regulators discuss available knowledge supporting COVID-19 medicine development
Last updated: 03/04/2020

News: COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes
Last updated: 01/04/2020

News: EU recommendations for 2020/2021 seasonal flu vaccine composition
CHMP, Last updated: 01/04/2020

Press release: Advancing regulatory science in the EU – new strategy adopted
Last updated: 31/03/2020

Press release: Update on treatments and vaccines against COVID-19 under development
Last updated: 31/03/2020
European Vaccine Initiative  [to 28 Mar 2020]
Latest News
No new digest content identified.
FDA [to 28 Mar 2020]
Press Announcements
April 3, 2020 – Coronavirus (COVID-19) Update: Daily Roundup April 3, 2020

…The FDA announced that it is leading an effort, working collaboratively with government, industry and academic partners, to develop and implement a protocol that will provide convalescent plasma to patients in need across the country who may not have access to institutions with clinical trials in place.  Convalescent plasma has the potential to lessen the severity or shorten the length of illness caused by COVID-19. This collaboration, involving BARDA, the American Red CrossExternal Link Disclaimer and the Mayo ClinicExternal Link Disclaimer, will allow for a simplified process for health care providers that will help ensure patient safety while allowing for the collection of needed information about product efficacy. The FDA anticipates that the effort will be able to move thousands of units of plasma to patients who need them in the coming weeks… 

April 3, 2020 – Coronavirus (COVID-19) Update: FDA Coordinates National Effort to Develop Blood-Related Therapies for COVID-19

April 2, 2020 – Coronavirus (COVID-19) Update: FDA Provides Updated Guidance to Address the Urgent Need for Blood During the Pandemic
Fondation Merieux  [to 28 Mar 2020]
News, Events
No new digest content identified.
Gavi [to 28 Mar 2020]
Top Stories
COVID-19: massive impact on lower-income countries threatens more disease outbreaks
:: At least 13.5 million people to miss out on vaccinations due to postponement of campaigns and interruptions in routine vaccinations, with millions more likely to follow
:: Gavi, the Vaccine Alliance is urgently providing support for countries’ COVID-19 response and in addition is ready to support mass vaccination campaigns once lockdowns finish
:: Dr Seth Berkley: “The legacy of COVID-19 must not include the global resurgence of other killers like measles and polio.”
Geneva, 3 April 2020

Modelling suggests suppression strategy will save more lives from COVID-19 in poor countries
Imperial model of the spread of COVID-19 implies a suppression strategy could be most effective.
1 April 2020
GHIT Fund   [to 28 Mar 2020]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that March 31, 2020
GHIT Fund Announces New Investments: A Total of 3.29 Billion Yen in Drugs for Malaria, Tuberculosis, Chagas Disease, Lymphatic Filariasis, and Onchocerciasis, Vaccines for Malaria, and Diagnostics for Leishmaniasis and Mycetoma

March 31, 2020
Statement: The Global Health Innovative Technology Fund and Unitaid collaboration to accelerate access to innovative solutions
Global Fund  [to 28 Mar 2020]
News & Stories
Funding Model
COVID-19 Response: Adaptations, Guidelines and Flexibilities for Countries
03 April 2020
Funding Model
COVID-19 Response: Continued Principal Recipient Reporting
02 April 2020

Funding Model
Funding Request Submission Dates Updated
31 March 2020

Sourcing & Management of Health Products
COVID-19 Impact on Supply Chain Logistics: Assessment and Recommendations
30 March 2020
Hilleman Laboratories   [to 28 Mar 2020]
No new digest content identified.
Human Vaccines Project   [to 28 Mar 2020]
Press Releases
No new digest content identified.
IAVI  [to 28 Mar 2020]
Press Releases
April 1, 2020
IAVI Welcomes W. Ripley Ballou, M.D., as ADVANCE Program Lead and Principal Investigator
NEW YORK – APRIL 1, 2020 – IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, is pleased to announce the appointment of W. Ripley (“Rip”) Ballou, M.D., as ADVANCE Program Lead and Principal Investigator. This groundbreaking global initiative to accelerate the development of vaccines and new technologies to combat the AIDS epidemic in partnership with Africa is funded by the U.S. Agency for International Development (USAID) through the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR)…
International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
No new digest content identified.
International Generic and Biosimilar Medicines Association [IGBA]
IGBA urgent recommendations to keep medicine supply chains flowing
27 March 2020
[See Milestones above for detail]
Press Releases
No new digest content identified.
IFRC   [to 28 Mar 2020]
Selected Press Releases, Announcements
No new digest content identified.
IVAC  [to 28 Mar 2020]
No new digest content identified.
IVI   [to 28 Mar 2020]
Selected IVI News & Announcements
USask VIDO-InterVac and International Vaccine Institute collaborate on COVID-19 work
The International Vaccine Institute (IVI) of South Korea, a world-renowned international organization founded by the United Nations Development Programme, is collaborating with VIDO-InterVac at the University of Saskatchewan (USask) to better understand the virus causing the COVID-19 pandemic and to develop vaccines and potential treatments.
USask Research Profile and Impact
Mar 27, 2020
JEE Alliance  [to 28 Mar 2020]
Selected News and Events
No new digest content identified.
MSF/Médecins Sans Frontières  [to 28 Mar 2020]
Latest [Selected Announcements]
Ensuring medical care for vulnerable people in and around Paris as …
Project Update 3 Apr 2020

Borno state: In the face of the COVID-19 pandemic, other dise…
Project Update 3 Apr 2020

COVID-19: MSF launches its largest ever response in Belg…
Project Update 3 Apr 2020

Northwest Syria: “COVID-19 adds another layer of com…
Project Update 2 Apr 2020

COVID-19 pandemic brings new challenges to well-developed hea…
Interview 31 Mar 2020

Coronavirus disease COVID-19
MSF steps up COVID-19 response in Europe
Press Release 30 Mar 2020
National Vaccine Program Office – U.S. HHS  [to 28 Mar 2020]
NVAC 2020 Meetings
June 9-10, 2020 NVAC Meeting
September 23-24, 2020 Meeting (Virtual)
NIH  [to 28 Mar 2020]
Selected News Releases
No new digest content identified.
PATH  [to 28 Mar 2020]
Selected Announcements
PATH-led study finds commercially available reference diagnostic detects malaria with whole blood sample
April 1, 2020 by PATH
Commercially available diagnostic can effectively detect all malaria parasites, including cases with suspected gene mutations, with a whole blood sample.
Sabin Vaccine Institute  [to 28 Mar 2020]
Statements and Press Releases
Sabin Vaccine Institute Names David Salisbury, Jeffrey P. Libson to Board of Trustees, Philip K. Russell Retires to Advisory Role
Thursday, April 2, 2020
Past Chair & President Philip K. Russell Retires as Trustee, Assumes Advisory Role
WASHINGTON, D.C. – The Sabin Vaccine Institute (Sabin) today announced that Professor David Salisbury and Jeffrey P. Libson have been named to the Board of Trustees and Retired Major General Philip K. Russell will transition from Trustee to Special Advisor after more than 25 years of service to the organization.

Each with some 40 years of experience, Salisbury and Libson bring additional global immunization policy and legal expertise to Sabin’s board. Salisbury is a well-respected leader in immunization program policy, vaccine research and disease eradication and Libson is a corporate and transactional attorney to the life sciences community who has also provided legal expertise to a number of non-profit life science organizations…
UNAIDS [to 28 Mar 2020]
Selected Press Releases/Reports/Statements
2 April 2020
People living with HIV in the Republic of Moldova to receive free home delivery of antiretroviral therapy

1 April 2020
A tribute to Gita Ramjee
UNICEF  [to 28 Mar 2020]

Press release
WHO and UNICEF to partner on pandemic response through COVID-19 Solidarity Response Fund
Unprecedented fund an ‘all hands on deck’ approach to tackle COVID-19 pandemic

Press release
IPA, WHO and UNICEF launch Read the World on International Children’s Book Day to support children and young people in isolation
Geronimo Stilton author to kickstart exclusive children’s book reading initiative amid COVID-19 pandemic

COVID-19 pandemic could devastate refugee, migrant and internally displaced populations without urgent international action
Statement by UNICEF Executive Director Henrietta Fore
NEW YORK, 1 April 2020 – “COVID-19 will almost certainly gain a foothold in refugee camps, crowded reception centers or detention facilities holding migrant families. Given how quickly the virus is spreading, such a scenario is looking imminent.
“Even absent a pandemic, uprooted children and families – those living as refugees, migrants or internally displaced – face immense barriers to accessing healthcare and preventative services like proper handwashing and sanitation facilities. So, when an infectious disease hits, their risk is compounded.

“An outbreak of a respiratory disease like COVID-19 could spread easily through the overcrowded confines and unsafe conditions typical of many camps or settlements. Families in these environments would be more likely to get sick and less capable of fighting off the disease because of inadequate services.

“We are not talking about a small number of people either. Today, there are 31 million children who have been uprooted from their homes, including over 17 million internally displaced, 12.7 million refugees and 1.1 million asylum seekers. All of them need some form of assistance. Most of them do not have the luxury of calling a doctor when sick, of washing their hands whenever they need to, or of practicing physical distancing to stop disease transmission.

“Any public health response to the pandemic should reach the most vulnerable, including refugees, migrants and those who are internally displaced. This means ensuring equitable access to testing and treatment as well as access to prevention information and to water and sanitation services. There should be plans in place for safe, family-based care and support for children separated from their caregivers or whose caregivers die.

“It also means that containment measures, like border closures and movement restrictions, should not block children’s right to seek asylum and reunite with family members. Nor should it hinder aid agencies’ efforts to provide humanitarian aid. Uprooted children and families should be moved quickly out of harm’s way to adequate accommodations where they have access to water, soap, physical distancing and safety.

“UNICEF is working with partners to prevent the spread of the disease among refugee, migrant and displaced populations. This includes promoting hygiene practices that help prevent transmission in shelters, camps and other accommodation sites. It includes developing accurate, child friendly information on COVID-19 and materials to fight stigma and promote positive parenting. It also includes distributing hygiene supplies and providing access to water.

“But we cannot do this alone. Now, more than ever, governments and the international community should come together to protect the most vulnerable in these unprecedented times.”

Press release
Children in the Democratic Republic of the Congo at risk from killer measles, cholera epidemics
COVID-19 latest challenge facing battered health services

Press release
UNICEF supplies arrive in Italy to support COVID-19 response

Press release
Greater support needed for working families as COVID-19 takes hold – UNICEF and ILO
Newly released recommendations for businesses aim to help employers strengthen support for families during the pandemic
Unitaid  [to 28 Mar 2020]
Unitaid is a global development agency, hosted by the World Health Organization and its major donors are France, the United Kingdom, Brazil, Norway, Chile, the Republic of Korea, Spain and the Bill & Melinda Gates Foundation.

03 April 2020 | Statements

Medicines Patent Pool and Unitaid respond to access efforts for COVID-19 treatments and technologies

The Board of the Medicines Patent Pool (MPP) has decided to temporarily expand its mandate to include any health technology that could contribute to the global response to COVID-19 and where licensing could facilitate innovation and access. With the support of Unitaid, this will allow MPP to offer its intellectual property and licensing expertise to the World Health Organization (WHO) to assist the global effort in any way it can.

Both MPP and Unitaid underline their commitment to jointly ensure equitable and timely access to medicines and diagnostics by the most vulnerable populations, as stressed in the G20 Leaders’ 26 March 2020 Statement.

Marie-Paule Kieny, Chair of the MPP Governance Board, said, “In these difficult times, the MPP Board recognises the important role that MPP can play to increase access to life-saving products for those who need them most. And importantly, with time of the essence, to ensure that we make use of the expertise and mechanisms that already exist.”…
Vaccination Acceptance Research Network (VARN)  [to 28 Mar 2020]
No new digest content identified.
Vaccine Confidence Project  [to 28 Mar 2020]
Latest News & Archive
No new digest content identified.
Vaccine Education Center – Children’s Hospital of Philadelphia  [to 28 Mar 2020]
Coronavirus Updates
Frequently Asked Questions about Coronavirus Disease 2019 (COVID-19)
Last Updated: March 19, 2020
Get some fast facts about the coronavirus from CHOP and the CDC. The CDC will provide updated information as it becomes available.
Wellcome Trust  [to 28 Mar 2020]
News | 31 March 2020
Wellcome joins the UK government, industry and universities in a step-change to COVID-19 testing

Wellcome is supporting a step-change in COVID-19 testing by the UK government. This is a collaborative project, with partners including the NHS, Public Health England, diagnostics companies Thermo Fisher Scientific, QIAGEN and Randox, UK universities, Boots, Royal Mail and Amazon.
The Wistar Institute   [to 28 Mar 2020]
Press Releases
Apr. 1, 2020

The Wistar Institute Signs Lease at 3.0 University Place

Signed lease agreement of up to 10 years for 8,000 sf with options for additional space to support long-term needs. In addition to their own Wistar Discovery Center lab space, Wistar will launch programming and curate lab partnerships​ ​in the new facility and throughout the life sciences sector.

3.0 University Place will provide 250,000 sf of lab and office space, specifically targeting biomedical research and advanced life science companies, with estimated delivery of Q3 2021…
WFPHA: World Federation of Public Health Associations  [to 28 Mar 2020]
Latest News
No new digest content identified.
World Organisation for Animal Health (OIE)   [to 28 Mar 2020]
Press Releases
No new digest content identified.
ARM [Alliance for Regenerative Medicine]  [to 28 Mar 2020]
Press Releases
The Alliance for Regenerative Medicine to Host FDA Representatives for Webinar on Clinical Trial Guidance During COVID-19 on April 10, 2020
April 2, 2020
BIO    [to 28 Mar 2020]
Press Releases
2020 BIO International Convention Now Fully Digital
April 3, 2020
The Biotechnology Innovation Organization (BIO) announced today it will be moving the 2020 BIO International Convention scheduled for June 8-11 in San Diego to an online platform, in lieu of an in-person event for this year. The decision was based…
DCVMN – Developing Country Vaccine Manufacturers Network  [to 28 Mar 2020]
No new digest content identified.
IFPMA   [to 28 Mar 2020]
Selected Press Releases, Statements, Publications
IFPMA Backgrounder – COVID-19
03 April 2020
[See COVID-19 for detail]
PhRMA    [to 28 Mar 2020]

Selected Press Releases, Statements

The biopharmaceutical industry’s unique role in responding to COVID-19

Richard Moscicki, M.D.  April 2, 2020

As the outbreak of COVID-19, a disease caused by a novel strain of coronavirus, evolves in the United States and around the globe, both the private and public sectors are working around the clock to find solutions. America’s biopharmaceutical companies are working tirelessly to develop ways to diagnose, prevent and treat those with coronavirus.

Here is a closer look at four key ways the biopharmaceutical industry is fighting COVID-19:

  1. Developing Potential New Treatments and Vaccines

As part of its commitment to finding solutions for patients with COVID-19 and preventing others from becoming infected, PhRMA members have been donating investigational compounds that may have potential to treat coronavirus for emergency use and in clinical trials, including compounds formerly tested on other viral pathogens such as Ebola and HIV.

Companies are also deploying their own clinical trials as quickly as possible to test promising investigational antiviral agents.  Other members are researching novel and existing vaccine candidates to identify promising candidates that have the ability to protect people from coronavirus infection. Importantly, biopharmaceutical industry research and development programs are pursuing a wide diversity of approaches to the development of treatments and vaccines and are also seeking to reduce the most severe of related symptoms associated with COVID-19.

Multiple avenues to preventive measures include a variety of vaccine approaches including mRNA and DNA vaccines, vaccines using synthetic materials and therapeutic antibodies that could be used not only to treat COVID-19 but also as a temporary preventive treatment in the absence of a vaccine.

Treatments under investigation include antiviral approaches such as protease inhibitors and nucleotide analogs to slow or reduce viral infections and treatments to reduce the severity of pulmonary manifestations of COVID-19 such as IL-6 inhibitors to reduce the risk of “cytokine storm” and antibacterials and vaccines to reduce the risk of secondary pneumococcal pneumonia.  It is not just the number of shots on goal, but also the wide variety of approaches being taken, that optimizes the chances of finding successful disease treatment and prevention.

Companies are also leveraging existing technologies to provide the ability to rapidly upscale production once a potential vaccine candidate is identified. Many companies are already investing heavily to increase production capacity. Similar efforts are underway for small molecule and antibody treatments.

  1. Engaging with Public Partners to share knowledge

Responding effectively to a public health emergency requires close collaboration between public and private organizations around the world to share insights that could accelerate treatment and prevention strategies. Leading PhRMA member companies are collaborating with relevant U.S. and global public health authorities, including the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO), as well as public health authorities in China and Europe, to understand how pandemic preparedness platforms can be tailored to address the current emergency, and how to accelerate the development of potential treatments. Members are also sharing the learnings from clinical trials in real time with governments and other companies to advance the development of additional therapies

  1. Advancing Past Learnings

Up until the outbreak began, COVID-19, a disease caused by a novel strain of coronavirus, did not exist. The rapid pace at which researchers have been able to understand this strain and get medicines into human clinical trials is a testament to the lessons learned from past public health emergencies. Furthermore, the biopharmaceutical industry has the unparalleled advantage of decades of scientific research cultivated from experience with similar viruses, such as MERS, SARS and influenza. These previous public health emergencies have helped put the infrastructure and partnerships in place to enable a more rapid response to emerging threats.

  1. Manufacturing Production

Innovative biopharmaceutical companies have the capacity to manufacture and broadly disseminate vaccines and treatments to patients worldwide. America’s biopharmaceutical companies are already ramping up production capacity in anticipation of the discovery of an effective treatment or vaccine. They are also protecting the integrity of the pharmaceutical supply chain and keeping plants open to maintain a steady supply of medicines for patients. All the while, our member companies are staying in constant communication with the U.S. Food and Drug Administration.

The biopharmaceutical industry is committed to developing solutions to address this global public health emergency just as it has in the past. PhRMA member companies not only bring decades of expertise in infectious diseases, including other strains of coronavirus, but bring the infrastructure and technologies to allow them to quickly advance potential vaccine and treatment candidates to clinical trials and have the manufacturing capabilities and expertise to allow for quick scale up.

Read more about the industry’s contributions to the COVID-19 pandemic and our principles here.